The test combines a genetic risk analysis with behavioral and lifestyle assessments, and uses Thermo Fisher Scientific's TaqMan OpenArray for genotyping.
With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
